Cefpodoxime: Difference between revisions
ClaireLewis (talk | contribs) No edit summary |
|||
(8 intermediate revisions by 5 users not shown) | |||
Line 1: | Line 1: | ||
==General== | ==General== | ||
*Type: 3rd generation [[cephalosporin]] | *Type: 3rd generation [[cephalosporin]] | ||
*Dosage Forms: tablet | *Dosage Forms: tablet, oral suspension | ||
*Common Trade Names: Cefopodoxine Proxetil | *Dosage Strengths: tablet: 100mg, 200mg; oral suspension: 50mg/5mL, 100mg/5mL | ||
*Routes of Administration: PO | |||
*Common Trade Names: Cefopodoxine Proxetil, Vantin | |||
==Adult Dosing== | ==Adult Dosing== | ||
===[[Bronchitis]] (chronic)=== | |||
*200mg q 12 h for 10 days | |||
===Acute bacterial infection=== | |||
*200mg q 12 h for 10 days | |||
===[[Pharyngitis]]/Tonsillitis=== | |||
*100mg q 12 h for 5-10 days | |||
===Acute community acquired [[pneumonia]]=== | |||
*200mg q 12 h for 14 days | |||
===Acute rhino [[sinusitis]]=== | |||
*200mg q 12 h for 10 days | |||
===Skin and soft tissue infection=== | |||
*400mg q 12 h for 14 days | |||
===[[Urinary tract infection]], uncomplicated=== | |||
*100mg q 12 h for 7 days | |||
==Pediatric Dosing== | ==Pediatric Dosing== | ||
===General=== | |||
*Infant ≥2 months to children <12 years: 10mg/kg/day (maximum 200mg/dose) q 12 h | |||
*Children >12 years to adolescent: 100 to 400mg q 12 h | |||
===Specific indication=== | |||
* | *[[Bronchitis]] (chronic), acute bacterial infection | ||
* | **Adult dosing for Infant ≥2 months to children <12 years | ||
* | *[[Acute otitis media]] | ||
**Infant ≥2 months to children <12 years: 5mg/kg/dose (maximum 200mg/dose) q 12 h for 5 days, duration according to AAP recommendation <ref>Lieberthal A. et al.The Diagnosis and Management of Acute Otitis Media.Pediatrics Mar 2013, 131 (3) e964-e999</ref>: for children < 2 years or any age with sever symptoms; 10 day-course, age 2-**5 years with mild to moderate symptoms: 7 day-course; age ≥ 6 years with mild to moderate symptoms: 5 day-course | |||
*[[Pharyngitis]]/tonsillitis: | |||
**Infant ≥2 months to children <12 years: 5mg/kg/dose (maximum 100mg/dose) q 12 h for 5-10 days | |||
**Children >12 years to adolescent: adult dosing | |||
*Acute [[sinusitis]] | |||
* | **Infant ≥2 months to children <12 years: 5mg/kg/dose (maximum 200mg/dose) q 12 h for 10 days, ISDA recommend adding Clindamycin for 10-14 days in patients with failed initial therapy or at risk of antibiotic resistance (attending daycare, age <2 years, recently hospitalised, antibiotic used with in 1 month) <ref>Chow AW et.al. ISDA clinical practice guideline for acute bacterial rhino sinusitis in children and adult.Clinical Infect Dis.2012 Apr;54(8):e72-e112</ref> | ||
**Children >12 years to adolescent: adult dosing | |||
*Skin soft tissue infection and uncomplicated [[urinary tract infection]] | |||
**Children >12 years to adolescent: adult dosing | |||
==Special Populations== | ==Special Populations== | ||
Line 40: | Line 53: | ||
==Contraindications== | ==Contraindications== | ||
*Allergy to class/drug | *Allergy to class/drug | ||
*Caution: | |||
**Hypersensitivity to [[penicillin] | |||
**Renal impairment | |||
**Concurrent nephrotoxic agent | |||
**[[Seizure]] disorder | |||
**Recent antibiotic-associated [[colitis]] | |||
==Adverse Reactions== | ==Adverse Reactions== | ||
===Serious (<1%)=== | ===Serious (<1%)=== | ||
*Anaphylaxis | *[[Anaphylaxis]] | ||
*Hypotension | *[[Hypotension]] | ||
*Nephritis | *Nephritis | ||
*Pseudomembranous colitis | *Pseudomembranous colitis | ||
*[[Seizures]] | |||
*[[Leukopenia]] | |||
*[[Thrombocytopenia]] | |||
*[[Anemia]] | |||
*Exfoliative dermatitis | |||
*[[Stevens-Johnson Syndrome]] | |||
*C. diff associated [[diarrhea]] | |||
===Common=== | ===Common=== | ||
*Diaper rash | *Diaper rash | ||
* | *[[Diarrhea]] | ||
*Nausea/vomiting | *[[Nausea]]/[[vomiting]] | ||
*Abdominal pain | *[[Abdominal pain]] | ||
*Dyspepsia | |||
*[[Headache]] | |||
*[[Candidiasis]], vulvovaginal | |||
==Pharmacology== | ==Pharmacology== | ||
Line 61: | Line 90: | ||
==See Also== | ==See Also== | ||
==References== | |||
<references/> | <references/> | ||
[[Category:Pharmacology]] | |||
[[Category:Pharmacology]] [[Category:ID]] |
Latest revision as of 21:57, 19 September 2019
General
- Type: 3rd generation cephalosporin
- Dosage Forms: tablet, oral suspension
- Dosage Strengths: tablet: 100mg, 200mg; oral suspension: 50mg/5mL, 100mg/5mL
- Routes of Administration: PO
- Common Trade Names: Cefopodoxine Proxetil, Vantin
Adult Dosing
Bronchitis (chronic)
- 200mg q 12 h for 10 days
Acute bacterial infection
- 200mg q 12 h for 10 days
Pharyngitis/Tonsillitis
- 100mg q 12 h for 5-10 days
Acute community acquired pneumonia
- 200mg q 12 h for 14 days
Acute rhino sinusitis
- 200mg q 12 h for 10 days
Skin and soft tissue infection
- 400mg q 12 h for 14 days
Urinary tract infection, uncomplicated
- 100mg q 12 h for 7 days
Pediatric Dosing
General
- Infant ≥2 months to children <12 years: 10mg/kg/day (maximum 200mg/dose) q 12 h
- Children >12 years to adolescent: 100 to 400mg q 12 h
Specific indication
- Bronchitis (chronic), acute bacterial infection
- Adult dosing for Infant ≥2 months to children <12 years
- Acute otitis media
- Infant ≥2 months to children <12 years: 5mg/kg/dose (maximum 200mg/dose) q 12 h for 5 days, duration according to AAP recommendation [1]: for children < 2 years or any age with sever symptoms; 10 day-course, age 2-**5 years with mild to moderate symptoms: 7 day-course; age ≥ 6 years with mild to moderate symptoms: 5 day-course
- Pharyngitis/tonsillitis:
- Infant ≥2 months to children <12 years: 5mg/kg/dose (maximum 100mg/dose) q 12 h for 5-10 days
- Children >12 years to adolescent: adult dosing
- Acute sinusitis
- Infant ≥2 months to children <12 years: 5mg/kg/dose (maximum 200mg/dose) q 12 h for 10 days, ISDA recommend adding Clindamycin for 10-14 days in patients with failed initial therapy or at risk of antibiotic resistance (attending daycare, age <2 years, recently hospitalised, antibiotic used with in 1 month) [2]
- Children >12 years to adolescent: adult dosing
- Skin soft tissue infection and uncomplicated urinary tract infection
- Children >12 years to adolescent: adult dosing
Special Populations
- Pregnancy Rating: B
- Lactation: excreted in breast milk, not recommended for nursing women
- Renal Dosing
- Adult
- CrCl >30 mL/minute: dosage adjustment not needed
- CrCl <30 mL/minute: administer q 24 h
- Hemodialysis: 3 times/week following dialysis
- Pediatric: not defined
- Adult
- Hepatic Dosing: dosage adjustment not nescessary
Contraindications
- Allergy to class/drug
- Caution:
Adverse Reactions
Serious (<1%)
- Anaphylaxis
- Hypotension
- Nephritis
- Pseudomembranous colitis
- Seizures
- Leukopenia
- Thrombocytopenia
- Anemia
- Exfoliative dermatitis
- Stevens-Johnson Syndrome
- C. diff associated diarrhea
Common
- Diaper rash
- Diarrhea
- Nausea/vomiting
- Abdominal pain
- Dyspepsia
- Headache
- Candidiasis, vulvovaginal
Pharmacology
- Half-life: 2-3 h, prolonged to ~10 h if CrCl <30 mL/minute
- Metabolism: De-esterified in GI tract to active metabolite
- Excretion: Urine
- Mechanism of Action: Inhibit bacterial cell walls synthesis (binding to penicillin-binding proteins (PBPs)